BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24040146)

  • 1. Loss of the BRCA1-interacting helicase BRIP1 results in abnormal mammary acinar morphogenesis.
    Daino K; Imaoka T; Morioka T; Tani S; Iizuka D; Nishimura M; Shimada Y
    PLoS One; 2013; 8(9):e74013. PubMed ID: 24040146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BRIP1 helicase functions independently of BRCA1 in the Fanconi anemia pathway for DNA crosslink repair.
    Bridge WL; Vandenberg CJ; Franklin RJ; Hiom K
    Nat Genet; 2005 Sep; 37(9):953-7. PubMed ID: 16116421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling.
    Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT
    Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tightly controlled MRTF-A activity regulates epithelial differentiation during formation of mammary acini.
    Seifert A; Posern G
    Breast Cancer Res; 2017 Jun; 19(1):68. PubMed ID: 28592291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.
    De Nicolo A; Tancredi M; Lombardi G; Flemma CC; Barbuti S; Di Cristofano C; Sobhian B; Bevilacqua G; Drapkin R; Caligo MA
    Clin Cancer Res; 2008 Jul; 14(14):4672-80. PubMed ID: 18628483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel role of BRCA1 interacting C-terminal helicase 1 (BRIP1) in breast tumour cell invasion.
    Rizeq B; Sif S; Nasrallah GK; Ouhtit A
    J Cell Mol Med; 2020 Oct; 24(19):11477-11488. PubMed ID: 32888398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypoxic conditions induce a cancer-like phenotype in human breast epithelial cells.
    Vaapil M; Helczynska K; Villadsen R; Petersen OW; Johansson E; Beckman S; Larsson C; Påhlman S; Jögi A
    PLoS One; 2012; 7(9):e46543. PubMed ID: 23029547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the BRCA1-interacting protein Brip1/BACH1/FANCJ is driven by E2F and correlates with human breast cancer malignancy.
    Eelen G; Vanden Bempt I; Verlinden L; Drijkoningen M; Smeets A; Neven P; Christiaens MR; Marchal K; Bouillon R; Verstuyf A
    Oncogene; 2008 Jul; 27(30):4233-41. PubMed ID: 18345034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles.
    Seal S; Thompson D; Renwick A; Elliott A; Kelly P; Barfoot R; Chagtai T; Jayatilake H; Ahmed M; Spanova K; North B; McGuffog L; Evans DG; Eccles D; ; Easton DF; Stratton MR; Rahman N
    Nat Genet; 2006 Nov; 38(11):1239-41. PubMed ID: 17033622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutational analysis of the breast cancer susceptibility gene BRIP1 /BACH1/FANCJ in high-risk non-BRCA1/BRCA2 breast cancer families.
    Guénard F; Labrie Y; Ouellette G; Joly Beauparlant C; Simard J; ; Durocher F
    J Hum Genet; 2008; 53(7):579. PubMed ID: 18414782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRIP1, a potential candidate gene in development of non-BRCA1/2 breast cancer.
    Ouhtit A; Gupta I; Shaikh Z
    Front Biosci (Elite Ed); 2016 Jan; 8(2):289-98. PubMed ID: 26709662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimolecular characteristics and role of BRCA1 interacting protein C-terminal helicase 1 (BRIP1) in human tumors: a pan-cancer analysis.
    Wang R; Zhang J; Cui X; Wang S; Chen T; Niu Y; Du X; Kong J; Wang L; Jiang Y
    World J Surg Oncol; 2023 Mar; 21(1):91. PubMed ID: 36907870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J.
    Levitus M; Waisfisz Q; Godthelp BC; de Vries Y; Hussain S; Wiegant WW; Elghalbzouri-Maghrani E; Steltenpool J; Rooimans MA; Pals G; Arwert F; Mathew CG; Zdzienicka MZ; Hiom K; De Winter JP; Joenje H
    Nat Genet; 2005 Sep; 37(9):934-5. PubMed ID: 16116423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic RAS regulates BRIP1 expression to induce dissociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence.
    Tu Z; Aird KM; Bitler BG; Nicodemus JP; Beeharry N; Xia B; Yen TJ; Zhang R
    Dev Cell; 2011 Dec; 21(6):1077-91. PubMed ID: 22137763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment.
    Monteiro LJ; Khongkow P; Kongsema M; Morris JR; Man C; Weekes D; Koo CY; Gomes AR; Pinto PH; Varghese V; Kenny LM; Charles Coombes R; Freire R; Medema RH; Lam EW
    Oncogene; 2013 Sep; 32(39):4634-45. PubMed ID: 23108394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation.
    Oberst MD; Beberman SJ; Zhao L; Yin JJ; Ward Y; Kelly K
    BMC Cancer; 2008 Jul; 8():189. PubMed ID: 18597688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation.
    Burleigh A; McKinney S; Brimhall J; Yap D; Eirew P; Poon S; Ng V; Wan A; Prentice L; Annab L; Barrett JC; Caldas C; Eaves C; Aparicio S
    Breast Cancer Res; 2015 Jan; 17():4. PubMed ID: 25572802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ETS transcription factor ELF5 induces lumen formation in a 3D model of mammary morphogenesis and its expression is inhibited by Jak2 inhibitor TG101348.
    Chean J; Chen CJ; Shively JE
    Exp Cell Res; 2017 Oct; 359(1):62-75. PubMed ID: 28800960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
    Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
    Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.